NCT07217015

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Dose-ranging Study With an Open-label Period Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Kymera Therapeutics, Inc. · Industry
• Sex: All
• Age: 12 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This phase 2b study is designed to evaluate the safety and efficacy of KT-621 in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD), a common form of eczema. The main goals of this study are to learn how effective KT-621 is at reducing the severity and extent of AD, the safety and tolerability of KT-621, how KT-621 behaves in the body, and how the body responds to KT-621. This is a 16-week double-blind, placebo-controlled study with a 52-week open-label period.

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	KT-621	Oral drug
OTHER	Placebo	Oral placebo matched to KT-621

Timeline

• Start date: 2025-11-24
• Primary completion: 2027-06-01
• Completion: 2028-06-01
• First posted: 2025-10-15
• Last updated: 2026-04-08

Locations

49 sites across 7 countries: United States, Australia, Canada, Czechia, Germany, Japan, Poland

Regulatory

• FDA-regulated drug study